Indomethacin delays progression of ALL in vivo. (A) Xenograft ALL#18 mice (5 mice per treatment group) were treated with indomethacin or vehicle as described in “Materials and methods." Progression of leukemia was followed by noninvasive in vivo imaging of luminescence from the mice. The images were taken 10 weeks after IT injection. (B) End point flow cytometry analysis of human CD19⁺CD10⁺ leukemic cells in the total bone marrow (left) and spleen (right) cell populations of the mice presented in panel A. Each circle represents the percentage of human CD19⁺CD10⁺ cells in the total spleen or bone marrow cell populations of 1 mouse. Horizontal lines represent the mean of each treatment group, *P < .05 (unpaired Student t test). (C) Weight of spleens from the mice presented in panel A. Each circle represents the spleen weight (g) of 1 mouse. Horizontal lines represent the mean of each treatment group, *P = .05 (unpaired Student t test). (D-E) End point flow cytometry analysis of CD19⁺CD10⁺ leukemic cells in the bone marrow of xenograft ALL#20 (D) and ALL#32 (E) mice. Each circle represents the percentage of human CD19⁺CD10⁺ cells in the total bone marrow cell population of 1 mouse. Horizontal lines represent the mean of each treatment group, *P < .05, **P < .01 (unpaired Student t test).